Chilean Cobalt Corp. is progressing its copper-cobalt projects in Chile's San Juan District and holds interests in the NeoRe rare earth project in southern Chile. These minerals are crucial for batteries, power infrastructure, and advanced technologies, sectors seeing increased demand due to electrification and defense needs. The company continues exploration to expand its portfolio, positioning itself to benefit from the growing market for critical minerals essential to modern technology and energy solutions.
Chilean Cobalt's copper and cobalt projects provide context for this Basic Materials sector snapshot. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 02, 2026 02:41 WIB: of 38 priced US stocks, 9 rose and 28 fell. Sibanye Stillwater Ltd (SBSW) traded at USD 10.01 with a 1-day change of -1.96% and Pluang order activity showing 11% Sell / 89% Buy, Johnson Controls International PLC (JCI) was at USD 151.46 with a 1-day change of +1.89%, and Barrick Gold Corp (B) traded at USD 40.03 with a 1-day change of -1.55% and 0% Sell / 100% Buy on Pluang.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
